Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL.

Fiedler ERC, Bhutkar A, Lawler E, Besada R, Hemann MT.

Blood Adv. 2018 Jun 12;2(11):1229-1242. doi: 10.1182/bloodadvances.2017015610.

2.

A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling.

Kauke MJ, Tisdale AW, Kelly RL, Braun CJ, Hemann MT, Wittrup KD.

Mol Cancer Ther. 2018 Aug;17(8):1773-1780. doi: 10.1158/1535-7163.MCT-17-0645. Epub 2018 May 2.

PMID:
29720559
3.

Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.

Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, Kaya T, Shi X, Robers MB, Machleidt T, Wilkinson J, Hermine O, Kung A, Stein AJ, Lakshminarasimhan D, Hemann MT, Scolnick E, Zhang YL, Pan JQ, Stegmaier K, Holson EB.

Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460. doi: 10.1126/scitranslmed.aam8460.

PMID:
29515000
4.

Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.

Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP.

Nat Commun. 2018 Feb 7;9(1):628. doi: 10.1038/s41467-018-02963-0.

5.

Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.

Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP.

Nat Commun. 2017 Dec 18;8(1):2166. doi: 10.1038/s41467-017-02390-7. Erratum in: Nat Commun. 2018 Feb 7;9(1):628.

6.

Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma.

Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, Agar NYR, Yaffe MB, Sharp PA, Hemann MT, Lees JA.

Cancer Cell. 2017 Oct 9;32(4):411-426.e11. doi: 10.1016/j.ccell.2017.08.018. Epub 2017 Sep 28.

PMID:
28966034
7.

Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?

Yamanaka K, Chatterjee N, Hemann MT, Walker GC.

PLoS Genet. 2017 Aug 17;13(8):e1006842. doi: 10.1371/journal.pgen.1006842. eCollection 2017 Aug. Review. No abstract available.

8.

Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.

Tang YC, Yuwen H, Wang K, Bruno PM, Bullock K, Deik A, Santaguida S, Trakala M, Pfau SJ, Zhong N, Huang T, Wang L, Clish CB, Hemann MT, Amon A.

Cancer Res. 2017 Oct 1;77(19):5272-5286. doi: 10.1158/0008-5472.CAN-17-0049. Epub 2017 Aug 3.

PMID:
28775166
9.

Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer.

Ramos A, Hemann MT.

Cell. 2017 Jul 27;170(3):411-413. doi: 10.1016/j.cell.2017.07.018.

10.

Transcription elongation factors represent in vivo cancer dependencies in glioblastoma.

Miller TE, Liau BB, Wallace LC, Morton AR, Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, Mack SC, Hubert CG, Gillespie SM, Flavahan WA, Hoffmann T, Thummalapalli R, Hemann MT, Paddison PJ, Horbinski CM, Zuber J, Scacheri PC, Bernstein BE, Tesar PJ, Rich JN.

Nature. 2017 Jul 20;547(7663):355-359. doi: 10.1038/nature23000. Epub 2017 Jul 5.

11.

PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes.

Soto-Feliciano YM, Bartlebaugh JME, Liu Y, Sánchez-Rivera FJ, Bhutkar A, Weintraub AS, Buenrostro JD, Cheng CS, Regev A, Jacks TE, Young RA, Hemann MT.

Genes Dev. 2017 May 15;31(10):973-989. doi: 10.1101/gad.295857.117. Epub 2017 Jun 12.

12.

Induction of Necroptosis in Cancer Stem Cells using a Nickel(II)-Dithiocarbamate Phenanthroline Complex.

Flamme M, Cressey PB, Lu C, Bruno PM, Eskandari A, Hemann MT, Hogarth G, Suntharalingam K.

Chemistry. 2017 Jul 18;23(40):9674-9682. doi: 10.1002/chem.201701837. Epub 2017 Jun 27.

PMID:
28556445
13.

Modeling Tumor Clonal Evolution for Drug Combinations Design.

Zhao B, Hemann MT, Lauffenburger DA.

Trends Cancer. 2016 Mar;2(3):144-158. doi: 10.1016/j.trecan.2016.02.001. Review.

14.

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.

Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT.

Nat Med. 2017 Apr;23(4):461-471. doi: 10.1038/nm.4291. Epub 2017 Feb 27.

15.

The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K.

Nat Med. 2017 Mar;23(3):301-313. doi: 10.1038/nm.4283. Epub 2017 Feb 13.

16.

Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations.

Sun D, Dalin S, Hemann MT, Lauffenburger DA, Zhao B.

Sci Rep. 2016 Nov 7;6:36198. doi: 10.1038/srep36198.

17.

Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage.

Zheng YR, Suntharalingam K, Bruno PM, Lin W, Wang W, Hemann MT, Lippard SJ.

Inorganica Chim Acta. 2016 Oct 1;452:125-129. Epub 2016 Mar 25.

18.

The breast cancer stem cell potency of copper(ii) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles.

Eskandari A, Boodram JN, Cressey PB, Lu C, Bruno PM, Hemann MT, Suntharalingam K.

Dalton Trans. 2016 Nov 28;45(44):17867-17873. Epub 2016 Oct 24.

PMID:
27774561
19.

Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Barnes JC, Bruno PM, Nguyen HV, Liao L, Liu J, Hemann MT, Johnson JA.

J Am Chem Soc. 2016 Sep 28;138(38):12494-501. doi: 10.1021/jacs.6b06321. Epub 2016 Sep 14.

20.

A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses.

Bent EH, Gilbert LA, Hemann MT.

Genes Dev. 2016 Aug 15;30(16):1811-21. doi: 10.1101/gad.284851.116. Epub 2016 Aug 26.

21.

Rewiring the solid tumor epigenome for cancer therapy.

Braun CJ, Hemann MT.

Expert Rev Anticancer Ther. 2016 Sep;16(9):977-87. doi: 10.1080/14737140.2016.1212663. Epub 2016 Aug 5. Review.

PMID:
27410491
22.

The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-Cyclam Complex on Cancer Stem Cells.

Cressey PB, Eskandari A, Bruno PM, Lu C, Hemann MT, Suntharalingam K.

Chembiochem. 2016 Sep 15;17(18):1713-8. doi: 10.1002/cbic.201600368. Epub 2016 Aug 11.

PMID:
27377813
23.

Targeting MTHFD2 in acute myeloid leukemia.

Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K.

J Exp Med. 2016 Jun 27;213(7):1285-306. doi: 10.1084/jem.20151574. Epub 2016 Jun 20.

24.

Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation.

Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3892-900. doi: 10.1073/pnas.1600582113. Epub 2016 Jun 20.

25.

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.

Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU.

Oncogene. 2016 Sep 29;35(39):5119-31. doi: 10.1038/onc.2016.41. Epub 2016 Mar 21.

26.

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution.

Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT.

Cell. 2016 Mar 24;165(1):234-246. doi: 10.1016/j.cell.2016.01.045. Epub 2016 Feb 25.

27.

Correction to "A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy".

Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ.

J Am Chem Soc. 2016 Mar 9;138(9):3250. doi: 10.1021/jacs.6b01316. Epub 2016 Feb 26. No abstract available.

PMID:
26916820
28.

Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes.

Boodram JN, Mcgregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K.

Angew Chem Int Ed Engl. 2016 Feb 18;55(8):2845-50. doi: 10.1002/anie.201510443. Epub 2016 Jan 25.

PMID:
26806362
29.

A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.

Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB.

Cancer Cell. 2015 Dec 14;28(6):831. doi: 10.1016/j.ccell.2015.11.003. Epub 2015 Dec 14. No abstract available.

30.

A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.

Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB.

Cancer Cell. 2015 Nov 9;28(5):623-637. doi: 10.1016/j.ccell.2015.09.009. Erratum in: Cancer Cell. 2015 Dec 14;28(6):831.

31.

The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies.

Shingleton JR, Hemann MT.

PLoS One. 2015 Nov 20;10(11):e0143275. doi: 10.1371/journal.pone.0143275. eCollection 2015.

32.

A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy.

Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ.

J Am Chem Soc. 2015 Dec 2;137(47):14854-7. doi: 10.1021/jacs.5b10182. Epub 2015 Nov 18. Erratum in: J Am Chem Soc. 2016 Mar 9;138(9):3250.

33.

Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.

McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, Tretyakova N, Lees JA, Hemann MT, White FM, Samson LD.

Cancer Res. 2015 Aug 1;75(15):3127-38. doi: 10.1158/0008-5472.CAN-14-3616. Epub 2015 May 29.

34.

A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency.

Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y, Hemann MT, Jiang H.

EMBO Mol Med. 2015 Apr;7(4):438-49. doi: 10.15252/emmm.201404580.

35.

A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth.

Meacham CE, Lawton LN, Soto-Feliciano YM, Pritchard JR, Joughin BA, Ehrenberger T, Fenouille N, Zuber J, Williams RT, Young RA, Hemann MT.

Genes Dev. 2015 Mar 1;29(5):483-8. doi: 10.1101/gad.254151.114.

36.

Necroptosis-inducing rhenium(V) oxo complexes.

Suntharalingam K, Awuah SG, Bruno PM, Johnstone TC, Wang F, Lin W, Zheng YR, Page JE, Hemann MT, Lippard SJ.

J Am Chem Soc. 2015 Mar 4;137(8):2967-74. doi: 10.1021/ja511978y. Epub 2015 Feb 20.

37.

Reply to Azuaje: Predicting effective combined therapies for heterogeneous tumors.

Zhao B, Hemann MT, Lauffenburger DA.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):E4288. doi: 10.1073/pnas.1415737111. Epub 2014 Sep 24. No abstract available.

38.

A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex.

Suntharalingam K, Lin W, Johnstone TC, Bruno PM, Zheng YR, Hemann MT, Lippard SJ.

J Am Chem Soc. 2014 Oct 15;136(41):14413-6. doi: 10.1021/ja508808v. Epub 2014 Oct 6.

39.

Intratumor heterogeneity alters most effective drugs in designed combinations.

Zhao B, Hemann MT, Lauffenburger DA.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10773-8. doi: 10.1073/pnas.1323934111. Epub 2014 Jul 7.

40.

From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer.

Hemann MT.

Cancer Discov. 2014 May;4(5):516-8. doi: 10.1158/2159-8290.CD-14-0316.

41.

SYK is a critical regulator of FLT3 in acute myeloid leukemia.

Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, Hemann MT, Stegmaier K.

Cancer Cell. 2014 Feb 10;25(2):226-42. doi: 10.1016/j.ccr.2014.01.022.

42.

Sensitizing protective tumor microenvironments to antibody-mediated therapy.

Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Hallek M, Chen J, Hemann MT.

Cell. 2014 Jan 30;156(3):590-602. doi: 10.1016/j.cell.2013.12.041.

43.

Addressing genetic tumor heterogeneity through computationally predictive combination therapy.

Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT.

Cancer Discov. 2014 Feb;4(2):166-74. doi: 10.1158/2159-8290.CD-13-0465. Epub 2013 Dec 6.

44.

Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways.

Suntharalingam K, Johnstone TC, Bruno PM, Lin W, Hemann MT, Lippard SJ.

J Am Chem Soc. 2013 Sep 25;135(38):14060-3. doi: 10.1021/ja4075375. Epub 2013 Sep 16.

45.

Integrated network analyses for functional genomic studies in cancer.

Wilson JL, Hemann MT, Fraenkel E, Lauffenburger DA.

Semin Cancer Biol. 2013 Aug;23(4):213-8. doi: 10.1016/j.semcancer.2013.06.004. Epub 2013 Jun 27. Review.

46.

Unraveling tumor suppressor networks with in vivo RNAi.

Braun CJ, Hemann MT.

Cell Stem Cell. 2013 Jun 6;12(6):639-41. doi: 10.1016/j.stem.2013.05.020.

47.

Predicting cancer drug mechanisms of action using molecular network signatures.

Pritchard JR, Bruno PM, Hemann MT, Lauffenburger DA.

Mol Biosyst. 2013 Jul;9(7):1604-19. doi: 10.1039/c2mb25459j. Epub 2013 Jan 4.

48.

Defining principles of combination drug mechanisms of action.

Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):E170-9. doi: 10.1073/pnas.1210419110. Epub 2012 Dec 18.

49.

Understanding resistance to combination chemotherapy.

Pritchard JR, Lauffenburger DA, Hemann MT.

Drug Resist Updat. 2012 Oct;15(5-6):249-57. doi: 10.1016/j.drup.2012.10.003. Epub 2012 Nov 17. Review.

50.

Context-specific roles for paracrine IL-6 in lymphomagenesis.

Gilbert LA, Hemann MT.

Genes Dev. 2012 Aug 1;26(15):1758-68. doi: 10.1101/gad.197590.112.

Supplemental Content

Loading ...
Support Center